Hepatology - Virology Flashcards

1
Q

What kind of genome does HBV have?

A

DNA-virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the transmission route of HBV? What the ways in which this happens? (5)

A

Blood-to-blood
1. Sexual contact
2. Blood transfusion
3. Contaminated needles
4. Vertical transmission
5. Profession

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

There is a vaccine for [only HBV/only HCV/both]

A

Only HBV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

There is curative treatment for [only HBV/only HCV/both]

A

Only HCV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Which cell type is targeted by HBV?

A

Hepatocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

HBV is usually [symptomatic/asymptomatic] in children, and [symptomatic/asymptomatic] in adults

A

Children = asymptomatic
Adults = symptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is the chance of HBV infection becoming chronic in newborns, children & adults?

A

Newborns: 90% becomes chronic
Children (<5): 30% becomes chronic
Adults: 10% becomes chronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

What is the disease pathogenesis of chronic HBV/HCV?

A

Inflammation -> fibrosis -> cirrhosis -> liver failure and/or HCC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What kind of genome does HCV have?

A

RNA-virus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is the transmission route of HCV? What the ways in which this happens? (5)

A

Blood-to-blood
1. Sexual contact
2. Blood transfusion
3. Contaminated needles
4. Vertical/perinatal transmission
5. Profession

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the most important way(s) that HBV and HCV are transmitted?

A

HBV: vertical transmission & sexual contact
HCV: sexual contact & contaminated needles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Which cell type does HCV target?

A

Hepatocytes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

HCV is [largely symptomatic/largely asymptomatic]

A

HCV = asymptomatic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the chance of HCV infection being acute vs. becoming chronic?

A

20-40% = acute
60-80% = chronic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the difference between HBV & HCV when it comes to type I IFN responses?

A

HBV = stealth virus -> avoids triggering IFN response
HCV = suppressive –> does trigger IFN response, but suppresses it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

By which mechanisms does HBV lower transcription of type I IFNs? (4)

A
  1. HBV sub-viral particles suppress TLR9 signalling in DCs
  2. HBeAg suppresses TLR2/TLR4 signalling in hepatocytes -> no NF-κB and IRF-genes
  3. HBV polymerase impairs nuclear translocation of STAT -> no interferon-stimulated genes
  4. HBx prevents RIG-I to MAVS signalling
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

What are the characteristics of HBV-directed T-cell responses?

A
  1. Lack of an innate resposne -> insufficient antigen presentation
  2. Lack of CD4+ T-cell help
  3. Exhaustion by prolonged antigen exposure
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What determines the chance of viral clearance in HCV infections?

A

Magnitude & breadth (=amount of epitopes covered) of the T-cell response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Through which mechanisms can HBV and HCV lead to HCC? (4)

A
  1. Integration of viral DNA into host DNA
  2. Inflammation/fibrosis
  3. Cellular/mitochondrial stress -> ROS -> DNA damage
  4. Lower CD8+ T-cell activity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

How many people are chronically infected with HBV? How many deaths does this virus cause each year?

A

296 million chronically infected
~820.000 deaths/year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

How many people are chronically infected with HCV? How many deaths does this virus cause each year?

A

58 million chronically infected
~290.000 deaths/year

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What was the treatment of HCV prior to the introduction of viral inhibitors?

A

PEG-IFN-α + ribavirin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

What is the benefit of pegylating IFN-α for the treatment of viruses?

A

Increases the half-life of IFN-α

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

What is the benefit of adding ribavirin to IFN-α treatment?

A

Increases potency of IFN-α

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

How many % of PEG-IFN-α recipients are cured?

A

61%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

What is the cause for the relatively low response rate of IFN-α treatment?

A

Specific genotypes are not sensitive

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

What is the main drawback of IFN-α + ribavirin treatment for HCV?

A

Long treatment duration (48 weeks) with severe side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

What are the side effects of IFN-α treatment? (5)

A
  1. Mild sickness
  2. Headache
  3. Fatigue
  4. Heart & kidney failure
  5. (Severe) depression & mood swings
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

What are the side effects of ribavirin treatment? (3)

A
  1. Nausea
  2. Itching
  3. Anaemia
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Why did many people not complete the complete course of IFN-α treatment?

A

They were mostly asymptomatic prior to treatment -> treatment caused severe decrease in QoL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Which types of interferons are there?

A

Type I, II & III

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

Which interferons belong to type I?

A

IFN-α, -β, -δ, -ε, -κ, -ω

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

Which interferon belongs to type II?

A

IFN-γ

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

Which interferons belong to type III?

A

IFN-λ1 (IL-29), -λ2 (IL-28A), -λ3 (IL-28B)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

What is the difference between type I and type III interferon signalling? What could make it more suitable for treatment of chronic viral disease?

A

Receptor distribution -> type I IFN receptor can be found throughout the body, while type III receptor is present on a more limited amount of cell types

Result: fewer side effects

36
Q

True or false: type III IFNs show a weaker antiviral response than type I IFNs

A

False: the antiviral response is clinically similar

37
Q

Type III IFNs are clinically effective & have fewer side effects than IFN-α. Why were they never introduced for treatment of chronic HCV?

A

Introduction of viral polymerase/protease inhibitors with higher efficacy

38
Q

Which important condition had to be met before viral inhibitors for HCV could be introduced?

A

Enabling of HCV viral culture -> allows for discovery of targets & testing

39
Q

What is the curation rate of polymerase/protease inhibitors for chronic HCV?

40
Q

What is seen as curation of chronic HCV?

A

Elimination of HCV RNA

41
Q

True or false: there is growing resistance against viral inhibitors for HCV

A

False: no resistance has been identified

42
Q

What are the remaining challenges in the field of HCV?

A
  1. Identifying all HCV patients
  2. Distributing available treatments across the world
43
Q

In which regions do most HBV infections occur?

A
  1. Asia
  2. Africa
44
Q

What are the effects of HBV vaccine on a population level? (4)

A
  1. Lower % of population infected with chronic HBV
  2. Decrease of liver cirrhosis/chronic liver disease
  3. Decrease of HCC mortality
  4. Decease of HCC incidence
45
Q

What is the most common way of HBV diagnostics? What are its advantages? (2)

A

HBsAg ELISA

  1. Cheap & widely available
  2. Reliable
46
Q

Which biomarkers are used for HBV monitoring during treatment? (3)

A
  1. HBV DNA
  2. HBeAg/HBeAb
  3. Liver transaminases (ALAT/ASAT)
47
Q

Which group of chronic HBV patients is treated with viral replication inhibitors?

A

Only patients with elevated HBV DNA & ALAT/ASAT

48
Q

What is the main treatment of chronic HBV?

A

Nucleoside analogues (NA)

49
Q

What is the effect of nucleoside analogues on HBV replication?

A

Cause chain termination -> suppresses replication

50
Q

What makes nucleoside analogues for HBV treatment HBV specific?

A

They specifically inhibit the reverse transcription on HBV -> no off-target effects in human cell replication

51
Q

What is the disadvantage of the use of nucleoside analogues for HBV treatment?

A

Life-long treatment required

52
Q

What are the currently used nucleoside analogues for HBV? (3)

A
  1. Tenofovir
  2. Entecavir
  3. Tenofovir alafenamide (TAF)
53
Q

What is the most important side effect of nucleoside analogues for HBV?

A

Decrease of kidney function when used for a long time in a small subset of patients

54
Q

True or false: nucleoside analogues cannot prevent vertical transmission of HBV

A

False; nucleoside analogues effectively prevent vertical transmission

55
Q

What are the options to prevent vertical transmission of HBV from mother to child? (2)

A
  1. Use of nucleoside analogues
  2. Use of anti-HBsAg during delivery
56
Q

What is an alternative of nucleoside analogue for HBV? What is its advantage? What is its disadvantage?

A

PEG-IFN
Advantage: has a 20-30 chance to fully clear the virus by targeting cccDNA
Disadvantage: severe side effects

57
Q

What is the main problem for HBV curation?

58
Q

Where is cccDNA located in the cell?

59
Q

What is the function of cccDNA

A

Can form a transcriptional template for all HBV RNAs -> allows for the production of new virus

60
Q

What is the most important difference between cccDNA and HBV DNA integrated into the host genome?

A

cccDNA is able to produce pre-genomic RNA (pgRNA), which can be used for the production of new HBV virus particles

HBV DNA in the host genome cannot do this

61
Q

What is the main disadvantage of HBV integration into the genome?

A

Can cause oncogenic mutations

62
Q

What are the effects of nucleoside analogues against HBV on a patient level? (4)

A
  1. Improves survival
  2. Delays the progression of cirrhosis
  3. Reduces (but does not eliminate) HCC risk
  4. Reduces the need for liver transplantation
63
Q

Which aspects of current HBV therapy need to be improved to enable curation? (3)

A
  1. Eradication of cccDNA
  2. Stimulate HBsAg seroconverson
  3. Get full immune control over the virus
64
Q

What is the current aim for an HBV cure?

A

Functional cure = sustained HBsAg-loss (s-loss) with or without seroconversion, with cccDNA still present

65
Q

Which three ‘levels of cure’ for HBV can be distinguished?

A
  1. Sterilizing cure
  2. Functional cure
  3. Partial cure
66
Q

What is meant with ‘sterilizing cure’ for HBV?

A

Complete elimination of all traces of HBV

67
Q

What is meant by ‘functional cure’ for HBV?

A

Sustained HBsAg-loss with or without seroconversion, cccDNA still present

68
Q

What is meant by ‘partial cure’ for HBV?

A

HBeAg & HBV DNA negative without treatment, but still HBsAg+

69
Q

What are the common targets of compounds that are currently investigated for the curation of HBV?

A
  1. Replication inhibition
  2. Antigen reduction
  3. Immune stabilization
70
Q

Which compounds aimed at replication inhibition of HBV are currently being tested? (3)

A
  1. Viral entry inhibitors
  2. Nucleoside analogues
  3. Capsid assembly modulators
71
Q

Which compounds aimed at antigen reduction for HBV are currently being tested? (3)

A
  1. Small interfering RNA (siRNA)
  2. Antisense oligonucleotides (ASO)
  3. RNA destabilizers
72
Q

What is the rationale of using antigen reduction to stimulate HBV curation?

A

Decreases antigen exposure, thus decreasing immune exhaustion

73
Q

Which compounds aimed at immune stabilization in HBV are currently being tested? (5)

A
  1. Cytokines
  2. TLR stimulation
  3. Vaccines
  4. Anti-HBsAg
  5. Immune checkpoint inhibitors
74
Q

What is the mechanism of action of capsid assembly modulators?

A

Disrupt HBV life cycle by destabilizing nucleocapsid/blocking DNA packaging -> production of particles without genetic information

75
Q

Are capsid assembly modulators for HBV being investigated for standalone use, or in concert with other compounds?

A

In combination with nucleoside analogues

76
Q

What are the side effects of capsid assembly modulators? (2)

A
  1. Rash
  2. ALAT flares
77
Q

What are the results of treatment with capsid assembly modulators + nucleoside analogues?

A
  1. Deeper viral load decline than NA alone
  2. No/modest HBsAg/HBeAg decline
78
Q

What is the function of siRNA in the clearance of HBV?

A

Can knock down production of all HBV genes & significantly decrease viral particles/antigens

79
Q

What is the mechanism of action of antisense oligonucleotides in the clearance of HBV?

A

Similar to siRNA: knock down production of HBV genes

80
Q

What is ‘s-loss’?

A

No HBsAg detectable in serum

81
Q

Which immune mechanisms promote HBV persistence in the liver? (8)

A
  1. Tregs
  2. IL-10 & TGF-β
  3. Regulatory B-cells
  4. Active elimination of T-cells
  5. Impaired NK-cells
  6. T-cell exhaustion
  7. Myeloid-derived suppressor cells
  8. Mitochondrial dysfunction
82
Q

What is the aim of the use of immunological compounds in the clearance of HBV?

A

Restore immune reactions to the levels of acute reaction -> enables viral clearance

83
Q

Which immune stimulatory compound are currently being used/tested for HBV curation?

A
  1. PEG-IFN
  2. TLR8 agonists
  3. Immune checkpoint inhibitors
  4. Therapeutic vaccination
84
Q

What are the advantages of using PEG-IFN in an HBV cure? (4)

A
  1. Well-characterized
  2. Dual mode of action: antiviral + immunomodulatory
  3. Proven to target cccDNA
  4. Higher s-loss than nucleoside analogues
85
Q

What are the disadvantages of using PEG-IFN in an HBV cure? (3)

A
  1. Toxicity
  2. Difficult to administer
  3. Low response rate
86
Q

What is the rationale behind using immune checkpoint inhibitors for an HBV cure?

A

Reverts T-cell exhaustion -> proliferation & activation of HBV-specific T-cells

87
Q

What is an overarching problem in the development of an HBV cure?

A

No HBV animal model available -> in vivo studies only possible in patients